 |
      
|
|
|
|
|
|||||
|
|
March 31, 2005
Neurochem to present at CIBC World Markets Annual Biotechnology & Specialty
Pharmaceuticals Conference. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The
Company's pipeline of proprietary, disease-modifying oral products addresses critical unmet medical needs. 1,3-
propanedisulfonate (1,3PDS; Fibrillex™) is designated as an orphan drug and a Fast Track Product candidate and is
also part of an FDA Continuous Marketing Applications Pilot 2 program. The Phase II/III clinical trial of
Fibrillex™ for the treatment of AA Amyloidosis was recently concluded and the study data are expected to be
released in the second quarter of 2005. 3-amino-1-propanesulfonic acid (3APS; AlzhemedT™), for the treatment of
Alzheimer's Disease, is in a Phase III clinical trial and 3APS (Cerebril™), for the prevention of Hemorrhagic
Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial. To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number
1 877 680-4500 or visit our Web Site at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable
at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are
beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions, general
conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem
does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to
consolidation, as well as other risks disclosed in public filings of Neurochem. Consequently, actual future results
may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not
place undue reliance, if any, on the forward-looking statements included in this news release. These statements speak
only as of the date made and Neurochem is under no obligation and disavows any intention to update or revise such
statements as a result of any event, circumstances or otherwise.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
